Interactive Pharma Solutions’ (IPS) Launches New eClinic Service - October 2022

Interactive Pharma Solutions’ (IPS) Selected to Build a Global Rare Disease Community - September 2022

Interactive Pharma Solutions’ (IPS) Digital Advisory Board Platform Highly Rated and Recommended by HCPs - July 2022

Interactive Pharma Solutions' (IPS) open new Boston Office on MIT Campus - June 2022

Interactive Pharma Solutions’ (IPS) Patient Platform has been selected to support and gather patient insights from clinical trials - March 2022

Interactive Pharma Solutions has launched a first of its kind patient support platform: PatientSelf.

A top five pharmaceutical company selected Interactive Pharma Solution’s PatientSelf platform to support patients with rheumatoid arthritis across Japan, Korea, China, and Singapore.

Utilising their extensive experience in creating HCP communities for the pharmaceutical industry, Interactive Pharma Solutions are creating digital advisory boards (DABs) for top five pharmaceutical companies.

With the increased emergence of health technologies and the effects of the COVID-19 pandemic, there is a need for global pharmaceutical companies to undergo a digital transformation. Interactive Pharma Solutions has drawn on over 30 years of digital experience to design a 3-point solution which will prepare organisations for the future of digital healthcare.

The Cancer App has been designed to patients stay in control of their care, appointments, medications and contacts, with relevant, expert information specific to their cancer.

IPS have a team of experts including Digital Strategists, Medical Professionals, HCP Strategists, Digital Advisors, Technical Advisors, UX, Digital Marketing, SEO and Compliance experts to name a few.

IPS is working with one of the world’s leading pharmaceutical companies to develop a community platform designed specifically for peer to peer scientific exchange medical education and clinical engagement.

Research capabilities in Africa are improving with more robustly trained local researchers working in better equipped facilities. This ensures that African countries lead and collaborate in all phases of early to late-stage clinical trials. The CTC saves on cost and time associated with landscape analysis and although it captures African clinical trials at the start, the aim is to expand the community to other parts of the world.

By bringing together our expert knowledge of digital healthcare, pharmaceuticals and global health, with Sana Labs’ expertise in the development and application of AI, we aim to establish a new level of digital innovation in the organisations we work with and for the people and patients they support.

Our new platform invites your target HCPs to join discussions and interact with surveys and polls that will generate real-time market and customer insights. Insights that will help shape and drive the success of your brand and commercial strategy.

“We are proud to announce the first GFGP certification in Africa, another huge milestone for us and a great achievement for the Institute of Primate Research.” says Prof Tom Kariuki, the Director of Programmes at the African Academy of Sciences.

The Centre for Genomic Pathogen Surveillance (CGPS), based jointly at the Oxford Big Data Institute and the Wellcome Sanger Institute, has supported the Bangalore-based Central Research Laboratory at Kempegowda Institute of Medical Sciences (CRL KIMS) to become the first organisation in the world to be certified under the Good Financial Grant Practice (GFGP) international standard (ARS 1651).

A team of radiologists and radiographers at Oxford University Hospitals has secured a grant to customise a teaching platform to educate frontline NHS staff to diagnose COVID-19 using chest X-rays and CT scans.

It is my pleasure to invite you to attend the Coalition for African Research and Innovation (CARI) Pharma Working Group’s next in-person meeting on Monday, 28 October 2019 in Addis Ababa, Ethiopia (exact time to be confirmed).